Niki BioSolutions, Inc.
corporate_fare Company Profile
Niki BioSolutions, Inc. (NASDAQ:NIKI) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 8 items for NIKI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-09, rated 7/10. Across its 8 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for NIKI spans 424B5, S-3/A, S-3, 8-K/A.
Recent high-impact activity:
- Niki BioSolutions Launches $1.4M ATM Program with Wainwright Amid Going-Concern Warning
- Niki BioSolutions S-3 Amendment Reveals Material Weaknesses, Going Concern Warnings, and RICO Lawsuit
- Niki BioSolutions Files $75M Shelf Registration Amid Going Concern Warning
- Niki BioSolutions Files Audited DiamiR Financials and Pro Forma Statements, Confirming Going Concern
- Niki BioSolutions Flags Going Concern, Weighs Financing After Post-Merger Losses
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 1,717 shares in NIKI as of the October 30, 2026 settlement, a 70.1% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 32.3% of NIKI volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for NIKI, detected from its recent SEC filings · based on capital-structure filings through 2026-10-09.
ATM Program Launched · Conflict of Interest Disclosed
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
NIKI files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.